Download PDF
Zentralbl Gynakol 2002; 124(2): 104-110
DOI: 10.1055/s-2002-24233
Originalarbeiten

© Georg Thieme Verlag Stuttgart · New York

Magnetic Resonance Female Breast Imaging (MRFBI)

Evaluation of the Changes in Signal Intensity over Time Pre- and Post-administration of 0.2 mmol/kg Gd-DTPAMagnetresonanztomographie der BrustEvaluation der zeitabhängigen Signalveränderung vor und nach Administration von 0,2 mmol/kg Gd-DTPAH. Schedel1 , H. Oellinger1 , P. Kohlschein2 , C. Siewert1 , J. Hadijuana1 , J. U. Blohmer3 , T. Kissner3 , R. Felix1
  • 1Department of Radiology, Charité, Campus Virchow Wedding, Humboldt-University, Medical Faculty, Augustenburger Platz 1, D-13353 Berlin
  • 2Institute of Clinical Chemistry and Pathobiochemistry, University of Rostock, Medical Faculty, Ernst Heydemann-Straße 6, D-18057 Rostock
  • 3Department of Obstetrics and Gynecology, Charité, Campus Charité Mitte, Humboldt-University Berlin, Medical Faculty, Schumannstraße 20/21, D-10117 Berlin
Further Information

Publication History

Publication Date:
04 April 2002 (online)

    Permissions and Reprints

Abstract

Purpose: We are looking for a threshold value to discriminate between benign and malign breast lesions in MRI of female breast after administration of 0.2 mmol Gadolinum-DTPA/kg bw.
Materials and Methods: Double coil breast MRI (1.5 Tesla) were performed in 65 patients with an suspicious lesion for malignancy in an anteriorly examination. 57 patients could be evaluated in our study design. Histopathological 35 patients had an invasive carcinoma, 3 patients had an in-situ-carcinoma and in 27 patients benign changes were found.
Results: For different carcinoma diameters we found a different increase of signal intensity (SI): small carcinoma (< 10 mm) had an maximum increase of SI of 102 %, medium sized (10 to 20 mm) 222 % and carcinomas over 20 mm showed an increase of 271 %. We did not find a significant difference between SI in benign and malign lesions. The sensitivity was 94.6 % the specificity 65 %.
Conclusion: A threshold value to distinguish between malign and benign in MRI could not be defined. With the double normal Gd-DTPA dose we do not have better specificity and sensitivity than for normal dose (0.1 mmol/kg bw) is described.

Key words

Breast Neoplasms - Magnetic Resonance Imaging - Contrast Media - Gadolinium DTPA - Sensitivity and Specificity

References

  • 1 Heywang-Köbrunner S H, Haustein J, Pohl C, Beck R, Lommatzsch B, Untch M, Nathrath W B. Contrast-enhanced MR imaging of the breast: comparison of two different doses of gadopentetate dimeglumine.  Radiology. 1994;  191 639-646
    PubMedSearch in Google Scholar
  • 2 Kaiser W A. Dynamic magnetic resonance breast imaging using a double breast coil: An important step toward routine examination of the breast.  Front Eur Radiol. 1990;  7 39-68
    PubMedSearch in Google Scholar
  • 3 Heywang-Köbrunner S H. Contrast-enhanced magnetic resonance imaging of the breast.  Invest Radiol. 1994;  29 94-104
    PubMedSearch in Google Scholar
  • 4 Kaiser W A, Zeitler E. MR-imaging of the breast: fast imaging sequences with and without Gd-DTPA.  Radiology. 1989;  170 681-686
    PubMedSearch in Google Scholar
  • 5 Harms S E, Flaming D P, Hesley K L. et al . MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation.  Radiology. 1993;  187 493-501
    PubMedSearch in Google Scholar
  • 6 Orel S G, Schnall M D, LiVolsi V A. et al . Suspicious breast lesions: MR imaging with radiologic-pathologic correlation.  Radiology. 1994;  190 121
    PubMedSearch in Google Scholar
  • 7 Mus R D, Boetes C, Holland R, Guijt W, Karssemeijer N, Barentsz J O. One-minute, single-section dynamic MR mammography with color-coded time, slope, and maximum signal intensity images: prelude to MR breast screening.  Radiology. 1994;  193 121
    PubMedSearch in Google Scholar
  • 8 Gribbestad I S, Nilsen G, Fjøsne H, Kvinnsland S, Haugen O A, Rinck P A. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography.  JMRI. 1994;  4 477-480
    PubMedSearch in Google Scholar
  • 9 Turkat T J, Klein B D, Polan R L, Richman R H. Dynamic MR mammography: a technique for potentially reducing the biopsy rate for benign breast disease.  JMRI. 1990;  4 563-568
    PubMedSearch in Google Scholar
  • 10 Flickinger F W, Allison J D, Sherry  R M, Wright J C. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI.  Magn Reson Imaging. 1993;  11 617-620
    PubMedSearch in Google Scholar
  • 11 Gilles R, Guinebretière J M. et al . Nonpalpable Breast Tumors: Diagnosis with contrast-enhanced subtraction dynamic MR imaging.  Radiology. 1994;  191 625-631
    PubMedSearch in Google Scholar
  • 12 Stalling C B, Hazle J D. MR imagining of the breast. A categorical course in breast imaging. Radiological Society of North America 1995; 185-197
  • 13 Kaiser W A. Magnetresonanztomographie der Mamma, Erfahrungen nach 253 Untersuchungen.  DMW. 1989;  114 1351-1357
    PubMedSearch in Google Scholar
  • 14 Kaiser W A. Moderne Diagnostik der Mamma.  Geburtsh Frauenheilkd. 1993;  53 1-14
    PubMedSearch in Google Scholar
  • 15 Stomper P C, Winston J S, Herman S, Klippenstein D L, Arredondo M A, Blumenson L E. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions.  Breast Cancer Res Treat. 1997;  45(1) 39-46
    CrossrefPubMedSearch in Google Scholar
  • 16 Buadu L D, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S, Ohno S. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.  Radiology. 1996;  100 639-649
    PubMedSearch in Google Scholar
  • 17 Gribbestad I S, Nilsen G, Fjøsne H, Fougner R, Haugen O A, Petersen S B, Rinck P A, Kvinnland S. Contrast-enhanced magnetic resonance imaging of the breast.  Acta Oncol.. 1992;  31 833-842
    PubMedSearch in Google Scholar

Dr. med. Peter Kohlschein

University of Rostock, Medical Faculty

Institute of Clinical Chemistry and Pathobiochemistry

Ernst-Heydemann-Straße 6

18057 Rostock

Phone: +49/381/494-7595

Fax: +49/381/494-7672

Email: peter.kohlschein@med.uni-rostock.de